Explore more publications!

Tech Portal Monaco: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Portal Monaco.

Press releases published on February 20, 2026

Constellation Software Inc. Announces Change to the Date of the Conference Call to Discuss Fourth Quarter Results
GreenBanana SEO celebrates 30th 5-star Google Review, Reinforcing Role as Best Generative Engine Optimization (GEO) Agency
iPower Reports Fiscal Q2 2026 Results and Completes Strategic Operating Reset
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Averin Capital Acquisition Corp. Completes $250,000,000 Initial Public Offering
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering  Including Full Exercise of Underwriter Option
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
Media87 Named 2026’s Top Digital Marketing Agency and Local SEO Leader
ESET’s Ryan Grant Named a 2026 CRN Channel Chief
ADARx Pharmaceuticals to Present Onvuzosiran (ADX-324) Phase 1/2 Clinical Data and Phase 3 Design at the 2026 AAAAI Annual Meeting
Big Blue Bubble Collaborates with T-Pain to Launch New 'Clubbox' Feature in My Singing Monsters
Gainwell Technologies and Medicaid Leaders to Highlight how States are Navigating H.R. 1 Requirements
Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development
20/20 BioLabs to Host Virtual Investor Webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval
SEALSQ and Quobly Mutually Agree to Halt Discussions Regarding a Potential Majority Investment or Acquisition by SEALSQ
CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions